| | 1 | = LhARA Steering Group meeting !#3 = |
| | 2 | |
| | 3 | //**3^rd^ July 2020 10:00 GMT**// |
| | 4 | |
| | 5 | == Agenda == |
| | 6 | |
| | 7 | 1. [wiki:Research/DesignStudy/PreCDR/SG/2020-06-05 Notes of last meeting and actions arising:] |
| | 8 | * **KL**: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme. |
| | 9 | * **Ongoing.** Need to step up the priority of this activity as we prepare the EPSRC proposal. |
| | 10 | * **KL/CB**: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF. |
| | 11 | * **Stands.** This meeting is necessary and, probably, should include Strathclyde and Belfast. |
| | 12 | * **KL/KK** to collaborate on the development for a proposal for such a meeting on the timescale of November 2020. |
| | 13 | * **Stands.** Agenda item. |
| | 14 | * **KL** Send out diary invitation straight away to get it into the diary. |
| | 15 | * **Done.** |
| | 16 | |
| | 17 | 2. [raw-attachment:2020-07-03-SGMeeting.pdf Project Managers report: AK \\ |
| | 18 | |
| | 19 | 3. Discussion of SG composition: KL/All |
| | 20 | |
| | 21 | 4. [https://epsrc.ukri.org/funding/calls/second-call-for-transformative-healthcare-technologies-pre-announcement-and-engagement-event/ EPSRC Transformative Healthcare Technologies call]: KL/All |
| | 22 | * Dealing with feedback from our 2019 submission: \\ |
| | 23 | "//Engagement with patients, clinicians and industry could have been strengthened//" |
| | 24 | - Patient engagement: |
| | 25 | - Actions taken to date; |
| | 26 | - Need for local action by partner; |
| | 27 | - Subsequent coordination |
| | 28 | * Clinician engagement: |
| | 29 | - Actions taken to date; |
| | 30 | - Need for local action by partner; |
| | 31 | - Subsequent coordination |
| | 32 | * Industrial engagement: |
| | 33 | - Actions taken to date; |
| | 34 | - Discussion of next steps |
| | 35 | * Slides to initiate discussion of: |
| | 36 | - Scope; |
| | 37 | - Initial discussion of work packages; |
| | 38 | - Stakeholders from whom we should be seeking support; |
| | 39 | - Next steps discussion |
| | 40 | |
| | 41 | 5. Follow-up Discussion of dedicated advanced diagnostics and instrumentation for the //in vitro// and //in vivo// end stations: KL/all |
| | 42 | |
| | 43 | 7. DONMs \\ |
| | 44 | * 04 Sep 2020; 10:00 BST |
| | 45 | |
| | 46 | 8. AoB \\ |
| | 47 | |
| | 48 | ---- |
